^68Ga-PSMA PET/CT在前列腺癌诊断中的研究进展  

Research progress of ^68Ga-PSMA PET/CT in the diagnosis of prostate cancer

作　　者：冯亚琪 崔邦平[1] 王朋[1] 代文莉[1] 邓鹏裔 田金玲[1] Feng Yaqi;Cui Bangping;Wang Peng;Dai Wenli;Deng Pengyi;Tian Jinling(Department of Nuclear Medicine,the First College of Clinical Medical Sciences,China Three Gorges University,Yichang Central People′s Hospital,Yichang Key Laboratory of Nuclear Medicine and Molecular Image,Yichang 443003,China)

机构地区：[1]三峡大学第一临床医学院、宜昌市中心人民医院核医学科、宜昌市核医学分子影像重点实验室,443003

出　　处：《中华核医学与分子影像杂志》2019年第4期237-240,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：宜昌市科学研究与开发项目(A13301-12);分子影像湖北省重点实验室开放基金项目(02.03.2015-150,02.03.2017-198).

摘　　要：前列腺癌的发病率近年呈现明显的上升趋势。18F-脱氧葡萄糖(FDG)是一种广谱的肿瘤显像剂,但在前列腺癌的应用上存在"盲区",开发性能更加优良的前列腺显像剂有助于弥补上述不足。目前已有多种正电子显像剂可用于前列腺癌显像,但总体优势并不明显。最近新的68Ga-前列腺特异膜抗原(PSMA)显像剂在前列腺癌的临床应用中显示出更好的价值,现就其研究进展予以综述。The incidence of prostate cancer has shown an obvious upward trend in recent years.^ 18F-fluorodeoxyglucose (FDG) is a broad-spectrum imaging agent for cancer, but there is a " blind zone" in the application of prostate cancer. Therefore, exploring prostate imaging agents with better performance can help to make up the deficiency. At present, there are a number of positron imaging agents for prostate cancer, but the overall advantage is not obvious. Recently, a new imaging agent, 68Ga-prostate specific membrane antigen (PSMA), has been demonstrated its better value in clinical application of prostate cancer. This review summarizes the research progress of 68Ga-PSMA.

关 键 词：前列腺肿瘤 前列腺特异膜抗原 同位素标记 镓放射性同位素 正电子发射断层显像术 体层摄影术 X线计算机 发展趋势 

分 类 号：R737.25[医药卫生—肿瘤]